Literature DB >> 11602626

CD4+CD28- costimulation-independent T cells in multiple sclerosis.

S Markovic-Plese1, I Cortese, K P Wandinger, H F McFarland, R Martin.   

Abstract

Multiple lines of evidence suggest that CD4+ lymphocytes initiate autoimmune responses against myelin antigens in multiple sclerosis (MS). The increased frequency of activated myelin-specific cells in MS patients indicates that the activation of autoreactive cells represents a central event in the pathogenesis of the disease. We identified a CD4+ subpopulation that is characterized phenotypically by the persistent absence of surface CD28 expression and functionally by CD28-independent activation and Th1 cytokine secretion. Owing to their costimulation-independent activation and their expression of a full agonist signaling activation pattern, CD4+CD28- cells have the potential to initiate autoimmune responses in the central nervous system, a compartment devoid of professional antigen presenting cells. Long-term memory CD4+CD28- cells produce high amounts of IFN-gamma and maximally upregulate IFN-gamma and IL-12Rbeta2 chain expression in the absence of costimulation. They exhibit prominent growth characteristics and increased survival after activation, likely related to their persistent lack of CTLA-4 surface expression. The CD4+CD28- population is expanded in a subgroup of MS patients. Myelin basic protein-specific cells detected in this cell subset may play an important role in the inflammatory response within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602626      PMCID: PMC209525          DOI: 10.1172/JCI12516

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients.

Authors:  T Strunk; S Bubel; B Mascher; P Schlenke; H Kirchner; K P Wandinger
Journal:  Ann Neurol       Date:  2000-02       Impact factor: 10.422

2.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Authors:  B Bielekova; B Goodwin; N Richert; I Cortese; T Kondo; G Afshar; B Gran; J Eaton; J Antel; J A Frank; H F McFarland; R Martin
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

4.  Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population.

Authors:  D E Anderson; K D Bieganowska; A Bar-Or; E M Oliveira; B Carreno; M Collins; D A Hafler
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

5.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.

Authors:  K Bachmaier; C Krawczyk; I Kozieradzki; Y Y Kong; T Sasaki; A Oliveira-dos-Santos; S Mariathasan; D Bouchard; A Wakeham; A Itie; J Le; P S Ohashi; I Sarosi; H Nishina; S Lipkowitz; J M Penninger
Journal:  Nature       Date:  2000-01-13       Impact factor: 49.962

6.  Human autoreactive CD4+ T cells from naive CD45RA+ and memory CD45RO+ subsets differ with respect to epitope specificity and functional antigen avidity.

Authors:  P A Muraro; M Pette; B Bielekova; H F McFarland; R Martin
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

7.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

8.  Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways.

Authors:  A N Vallejo; M Schirmer; C M Weyand; J J Goronzy
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

9.  Following the development of a CD4 T cell response in vivo: from activation to memory formation.

Authors:  S Garcia; J DiSanto; B Stockinger
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

10.  T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivo.

Authors:  M Fassò; N Anandasabapathy; F Crawford; J Kappler; C G Fathman; W M Ridgway
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

View more
  83 in total

1.  Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages.

Authors:  Stefan O Schönland; Consuelo Lopez; Thomas Widmann; Julia Zimmer; Ewa Bryl; Jörg J Goronzy; Cornelia M Weyand
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-24       Impact factor: 11.205

Review 2.  Immunopathogenesis of multiple sclerosis: MBP and beyond.

Authors:  E Meinl; R Hohlfeld
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

3.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 4.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

5.  Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells.

Authors:  Jaime García de Tena; Luis Manzano; Juan Carlos Leal; Esther San Antonio; Verónica Sualdea; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

6.  Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.

Authors:  D Eastwood; L Findlay; S Poole; C Bird; M Wadhwa; M Moore; C Burns; R Thorpe; R Stebbings
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

7.  Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.

Authors:  Alfredo Prieto; David Díaz; Hugo Barcenilla; Carmen Castrillo; Jorge Monserrat; Antonio García Merino; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

8.  Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy.

Authors:  Javad Rasouli; Bogoljub Ciric; Jaime Imitola; Patricia Gonnella; Daniel Hwang; Kedar Mahajan; Elisabeth R Mari; Farinaz Safavi; Thomas P Leist; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

9.  Killer cell immunoglobulin receptor profile on CD4(+)  CD28(-) T cells and their pathogenic role in non-dialysis-dependent and dialysis-dependent chronic kidney disease patients.

Authors:  Behnam Zal; Nihil Chitalia; Yin Sing Ng; Verna Trieu; Sana Javed; Rachelle Warrington; Juan Carlos Kaski; Debasish Banerjee; Christina Baboonian
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

10.  The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease.

Authors:  K Kamikozuru; K Fukunaga; S Hirota; N Hida; Y Ohda; K Yoshida; Y Yokoyama; K Tozawa; K Kawa; M Iimuro; K Nagase; A R Saniabadi; S Nakamura; H Miwa; T Matsumoto
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.